PATENT CLAIM ANALYSIS

Application Number: 15767914
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "253040"]

Abstract:
The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.

Claim (Index 17):
A pharmaceutical product comprising (i) a first composition comprising [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]{3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl}methanone (cobimetinib) or a pharmaceutically acceptable salt thereof, and (ii) a second composition comprising 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide (ABT-199) or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 91.0
- Lexical Diversity: 1.5625
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14122779', '14020761', '15116712', '15943229', '14473311']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7776167866022888
- 35 USC 102 Novelty (BERT): 0.5192070734936549
- Combined Prediction Score: 0.7517758152914255
- Mean Citation Score: 294.5926199999999
- Max Citation Score: 321.6076700000001
- Similarity Product: 235.9488373485161

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test